RxDoctor Payments Data

Mary Clarke, MD

Family Medicine · Stillwater, OKNPI 1194839589

Payments from drug & device makers

$628in general payments, 2019–2025

Across 36 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$148
  • Amarin Pharma, Inc.$95
  • AstraZeneca$66
  • Astellas Pharma US Inc$52
  • Merck$45
  • GSK$43
  • plus $180 from 10 others

What the payments were for

  • Food & beverage$60396%
  • Education$264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$628 in reported general payments places this provider in the 55th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$168,582
Medicare patients
743
Services billed
3,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$65,550
RybelsusSemaglutide25$25,371
OzempicSemaglutide25$21,714
XareltoRivaroxaban26$17,171
MounjaroTirzepatide14$14,617
JanuviaSitagliptin Phosphate16$13,249
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,178
TrulicityDulaglutide12$12,565
Wixela InhubFluticasone Propion/Salmeterol49$10,013
Atorvastatin Calcium329$5,063
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$3,811
Potassium Chloride87$2,755
Omeprazole192$2,555
Levothyroxine Sodium245$2,529
Lisinopril210$2,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$65,55074 claims
Novo NordiskRybelsus, Ozempic$15$47,08550 claims
Lilly USA, LLCMounjaro, Trulicity$27$27,18326 claims
Johnson & JohnsonXarelto$24$17,17126 claims
MerckJanuvia$45$13,24916 claims
GSKTrelegy Ellipta$43$13,17816 claims
AbbVieSynthroid$34$85211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →